BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28741260)

  • 21. Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.
    Azariadis K; Kiagiadaki F; Pelekanou V; Bempi V; Alexakis K; Kampa M; Tsapis A; Castanas E; Notas G
    Cell Physiol Biochem; 2017; 44(1):66-84. PubMed ID: 29131020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer.
    He L; Du Z; Xiong X; Ma H; Zhu Z; Gao H; Cao J; Li T; Li H; Yang K; Chen G; Richer JK; Gu H
    Sci Rep; 2017 Nov; 7(1):14584. PubMed ID: 29109513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
    Bronte G; Rocca A; Ravaioli S; Puccetti M; Tumedei MM; Scarpi E; Andreis D; Maltoni R; Sarti S; Cecconetto L; Fedeli A; Pietri E; De Simone V; Asioli S; Amadori D; Bravaccini S
    BMC Cancer; 2018 Mar; 18(1):348. PubMed ID: 29587674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.
    Cao L; Xu C; Xiang G; Liu F; Liu X; Li C; Liu J; Meng Q; Jiao J; Niu Y
    Mol Cancer; 2018 Sep; 17(1):136. PubMed ID: 30217192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-canonical AR activity facilitates endocrine resistance in breast cancer.
    Chia K; Milioli H; Portman N; Laven-Law G; Coulson R; Yong A; Segara D; Parker A; Caldon CE; Deng N; Swarbrick A; Tilley WD; Hickey TE; Lim E
    Endocr Relat Cancer; 2019 Feb; 26(2):251-264. PubMed ID: 30557851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
    Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating Adipose Fatty Acid Binding Protein Is a New Link Underlying Obesity-Associated Breast/Mammary Tumor Development.
    Hao J; Zhang Y; Yan X; Yan F; Sun Y; Zeng J; Waigel S; Yin Y; Fraig MM; Egilmez NK; Suttles J; Kong M; Liu S; Cleary MP; Sauter E; Li B
    Cell Metab; 2018 Nov; 28(5):689-705.e5. PubMed ID: 30100196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth and characterization of N-methyl-N-nitrosourea-induced mammary tumors in intact and ovariectomized rats.
    Thordarson G; Lee AV; McCarty M; Van Horn K; Chu O; Chou YC; Yang J; Guzman RC; Nandi S; Talamantes F
    Carcinogenesis; 2001 Dec; 22(12):2039-47. PubMed ID: 11751437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients.
    Mullooly M; Yang HP; Falk RT; Nyante SJ; Cora R; Pfeiffer RM; Radisky DC; Visscher DW; Hartmann LC; Carter JM; Degnim AC; Stanczyk FZ; Figueroa JD; Garcia-Closas M; Lissowska J; Troester MA; Hewitt SM; Brinton LA; Sherman ME; Gierach GL
    Breast Cancer Res; 2017 Jan; 19(1):8. PubMed ID: 28103902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers.
    Ogawa Y; Hai E; Matsumoto K; Ikeda K; Tokunaga S; Nagahara H; Sakurai K; Inoue T; Nishiguchi Y
    Int J Clin Oncol; 2008 Oct; 13(5):431-5. PubMed ID: 18946753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.
    Giles ED; Jindal S; Wellberg EA; Schedin T; Anderson SM; Thor AD; Edwards DP; MacLean PS; Schedin P
    Breast Cancer Res; 2018 Jun; 20(1):50. PubMed ID: 29898754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW; Lee KS
    Ann Oncol; 2011 Aug; 22(8):1755-62. PubMed ID: 21310761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats.
    Allred CD; Allred KF; Ju YH; Clausen LM; Doerge DR; Schantz SL; Korol DL; Wallig MA; Helferich WG
    Carcinogenesis; 2004 Feb; 25(2):211-8. PubMed ID: 14578162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vitamin D mitigates the adverse effects of obesity on breast cancer in mice.
    Swami S; Krishnan AV; Williams J; Aggarwal A; Albertelli MA; Horst RL; Feldman BJ; Feldman D
    Endocr Relat Cancer; 2016 Apr; 23(4):251-64. PubMed ID: 26817629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obesity-Activated Adipose-Derived Stromal Cells Promote Breast Cancer Growth and Invasion.
    Hillers LE; D'Amato JV; Chamberlin T; Paderta G; Arendt LM
    Neoplasia; 2018 Nov; 20(11):1161-1174. PubMed ID: 30317122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.
    Kwilas AR; Ardiani A; Gameiro SR; Richards J; Hall AB; Hodge JW
    Oncotarget; 2016 Apr; 7(17):23498-511. PubMed ID: 27015557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer.
    Salvi S; Bonafè M; Bravaccini S
    Semin Cancer Biol; 2020 Feb; 60():132-137. PubMed ID: 31002873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.